Highest-materiality recent filing
Nautilus Biotechnology FY2025 net loss narrows to $59M; cash $156M; guidance for higher 2026 spend
Q4 net loss of $13.8M vs $17.6M YoY; operating expenses down 23% to $15.4M.
Nautilus regains Nasdaq minimum bid price compliance; deficiency closed
Received notice on Nov 3, 2025 that closing bid price met $1 for 10 consecutive days.
Nautilus Q2 net loss narrows to $15.0M; cash $179.5M; platform milestone
Operating expenses $17.1M, down 18% YoY from $20.8M.
Received notice on May 1, 2025 for failing to maintain $1.00 minimum bid price for 30 consecutive business days through April 30, 2025.
Q4 2024 operating expenses flat at $20.0M; FY2024 op. expenses $81.5M (+7% YoY).
Nautilus Biotechnology enters $125M at-the-market equity offering with TD Cowen
Sales agreement with TD Cowen to sell up to $125M of common stock via ATM program.
Filed suit on Dec 14, 2023 in Northern District of California against Somalogic and Caltech.
Nautilus Biotechnology Q3 net loss $15.9M, op ex up 21% YoY to $19.1M
Net loss of $15.9M for Q3 2023 vs. $14.1M in Q3 2022.
Nautilus Q2 net loss $14.7M; cash $334.9M; platform launch on track for mid-2024
Operating expenses of $15.5M in Q2 2022, down from $16.0M in Q1 2022.
Nautilus Biotechnology reports FY2021 net loss of $50.3M; operating expenses up 221% to $50.5M
FY2021 net loss $50.3M, compared to $15.6M in 2020; operating expenses $50.5M, up 221%.
Nautilus Q3 net loss widens to $14.5M; OpEx up 262%; cash at $374M
Net loss of $14.5M for Q3 2021 vs. $4.0M loss in Q3 2020.
Nautilus Biotechnology Q2 2021 net loss of $10.7M; raised $345.5M in business combination
Completed business combination with ARYA Sciences, receiving gross proceeds of $345.5M.
each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors
Matthew McIlwain agreed to resign as a Class II director, effective as of the opening of the polls for the election of Class I directors at the Annual Meeting, and to stand for election to the Board as a Class I director at the Annual Meeting
each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors
On January 27 and 28, 2025, each of Vijay Pande and Michael Altman, respectively, informed Nautilus Biotechnology, Inc. (the “Company”) that they will not stand for re-election to the Company’s board of directors at the Company’s 2025 annual meeting of stockholders.
On January 27 and 28, 2025, each of Vijay Pande and Michael Altman, respectively, informed Nautilus Biotechnology, Inc. (the “Company”) that they will not stand for re-election to the Company’s board of directors at the Company’s 2025 annual meeting of stockholders.
On March 30, 2022 , the board of directors (the “Board”) of Nautilus Biotechnology, Inc. (the “Company”), upon recommendation of the Nominating and Governance Committee of the Board, appointed Karen Akinsanya to the Board, effective immediately.
Max materiality 0.75 · Median 0.50 · Most common event earnings